Lv11
78 积分 2025-09-23 加入
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
30天前
已完结
Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study
1个月前
已完结
Inebilizumab for Treatment of IgG4-Related Disease
1个月前
已完结
Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial
1个月前
已完结
A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus
1个月前
已完结
OP0186 EFFICACY AND SAFETY OF RILZABRUTINIB, AN ORAL BRUTON'S TYROSINE KINASE INHIBITOR, IN PATIENTS WITH IgG4-RELATED DISEASE: RESULTS FROM A 52-WEEK, PHASE 2, OPEN-LABEL, PROOF-OF-CONCEPT STUDY
1个月前
已关闭
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study
3个月前
已完结
皖公网安备34019202002308
